MedImmune snaps up beta cell regeneration portfolio from Evotec
This article was originally published in Scrip
Executive Summary
Through its subsidiary Develogen, Evotec has signed over exclusive access to its research portfolio focused on the regeneration of insulin producing beta cells to treat diabetes to MedImmune (AstraZeneca). This includes the lead asset EVT770, a novel beta cell regeneration factor, and a pipeline of selected additional secreted factors.